2023 Volume 35 Issue 3 Pages 115-121
Psoriatic disease is a systemic inflammatory disease, and is complicated by various pathologies other than skin and musculoskeletal conditions, including steatohepatitis. In particular, psoriatic diseases have a high risk of death from cardiovascular disease, and psoriatic arthritis has a significantly higher risk than psoriasis vulgaris. Enthesitis is reflected as a patient-reported outcome（PRO）and is significantly involved in QOL impairment in psoriasis patients. For these reasons, the degree of satisfaction with the treatment of psoriatic diseases is still low, and aggressive systemic therapeutic intervention from an early stage is desired. Although there are several treatment recommendations for psoriatic diseases, the final choice of therapeutic agent is left to the physician. IL-23 inhibitors are effective not only for skin lesions and enthesitis, but also for peripheral arthritis. It has also been reported that it may suppress the onset of psoriatic arthritis in psoriasis patients, and it is considered to be a drug that should be considered from an early stage.
